Astrotech Corp (ASTC) - Q3 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Astrotech Corporation (ASTC) is a Delaware corporation developing mass spectrometry and gas chromatography technologies for security, industrial, and agricultural applications. The company operates through wholly-owned subsidiaries including 1st Detect (security), AgLAB (agriculture), BreathTech (health), Pro-Control (industrial), and EN-SCAN (environmental). The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q3 2026 (3 Months) | Q3 2025 (3 Months) | YTD 2026 (9 Months) | YTD 2025 (9 Months) |
|---|---|---|---|---|
| Revenue | $343 | $534 | $787 | $829 |
| Gross Profit | $67 | $237 | $262 | $401 |
| Gross Margin | 20% | 44% | 33% | 48% |
| Operating Expenses | $3,520 | $4,104 | $11,152 | $12,217 |
| Net Loss | $(3,768) | $(3,633) | $(11,161) | $(10,920) |
| Net Loss Per Share | $(2.25) | $(2.18) | $(6.66) | $(6.57) |
| Cash & Equivalents | $2,679 | $3,100 (Jun '25) | $2,679 | $2,812 (Mar '25) |
| Short-term Investments | $3,903 | $15,108 (Jun '25) | $3,903 | $15,108 (Jun '25) |
| Working Capital | $9.5M | $19.5M (Jun '25) | $9.5M | N/A |
| Accumulated Deficit | $(262,030) | $(250,870) | $(262,030) | $(247,940) |
Material Changes vs. Prior Period
- Revenue Decline: Q3 revenue decreased 36% year-over-year to $343k, driven by lower product revenue and negative grant revenue due to re-testing costs. YTD revenue decreased 5% to $787k.
- Margin Compression: Gross margin dropped significantly from 44% to 20% in Q3. Management attributed this to the sale of obsolete consumables purchased at elevated costs during the COVID period, which were sold below cost to recover value rather than written off.
- Expense Reduction: Operating expenses decreased 14% in Q3 and 8.7% YTD. R&D expenses fell 28% in Q3 due to reduced consulting costs and a strategic shift toward sales initiatives.
- Liquidity Shift: Short-term investments decreased from $15.1M to $3.9M as the company liquidated approximately $11.7M in investments to fund operations. Cash and cash equivalents decreased by $421k YTD.
- Other Income: Other income turned negative in Q3 ($(315)k) compared to a gain of $234k in the prior year, primarily due to a $210k loss on asset disposal and realized losses on securities.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash ($2.7M) and short-term investments ($3.9M) are sufficient to fund operations for at least the next 12 months. However, substantial additional capital is required for long-term growth.
- Capital Raising: The company filed a Shelf Registration Statement (Form S-3) in January 2026, allowing for the sale of up to $30M in securities, though subject to a "Baby Shelf" limitation of approximately $1.97M based on current public float.
- Operational Milestones:
- 1st Detect: TRACER 1000 achieved ECAC/EU G1 approval (May 2026) and secured a $429k purchase order from a TSA-approved contractor in April 2025. First sale of the Narcotic Trace Detector occurred in Vietnam.
- AgLAB: Field trials indicate the AgLAB 1000-D2 can improve distillation yields by 15-30%.
- EN-SCAN: New subsidiary formed in Feb 2025 for environmental testing.
- Risks:
- Delisting Risk: The company's market value of listed securities falls below the proposed $5M Nasdaq threshold. If the new rule is adopted, the company could face accelerated delisting proceedings.
- Customer Concentration: For Q3 2026, one customer accounted for substantially all revenue ($99k). For YTD 2026, four customers accounted for substantially all revenue.
- Related Party Transactions: Incurred $211k in consulting expenses for services provided by the CEO's son-in-law during the nine months ended March 31, 2026.
Investor Verification Checklist
- Capital Adequacy: Verify the timeline for the next capital raise given the $262M accumulated deficit and $11.2M YTD net loss.
- Nasdaq Compliance: Monitor the status of the proposed Nasdaq $5M market value rule and the company's market cap to assess delisting risk.
- Revenue Quality: Investigate the sustainability of revenue given the heavy reliance on a single customer in Q3 and the negative impact of selling obsolete inventory on margins.
- Grant Revenue: Review the nature of the negative grant revenue in Q3 and the sustainability of future government contracts (e.g., DHS contract).
- Related Party Costs: Assess the necessity and market-rate justification for the $211k related-party consulting expense.